Prevalence, Awareness, and Treatment of Elevated LDL Cholesterol in US Adults, 1999-2020

Ahmed Sayed; Ann Marie Navar; Leandro Slipczuk; Christie M Ballantyne; Zainab Samad; Carl J Lavie; Salim S Virani

doi:10.1001/jamacardio.2023.3931

Prevalence, Awareness, and Treatment of Elevated LDL Cholesterol in US Adults, 1999-2020

JAMA Cardiol. 2023 Dec 1;8(12):1185-1187. doi: 10.1001/jamacardio.2023.3931.

Authors

Ahmed Sayed¹, Ann Marie Navar^{2

3}, Leandro Slipczuk⁴, Christie M Ballantyne⁵, Zainab Samad⁶, Carl J Lavie⁷, Salim S Virani⁶

Affiliations

¹ Faculty of Medicine, Ain Shams University, Cairo, Egypt.
² Division of Cardiology, Department of Medicine, University of Texas Southwestern Medical Center, Dallas.
³ Deputy Editor, Diversity, Equity, and Inclusion, JAMA Cardiology.
⁴ Division of Cardiology, Montefiore Healthcare Network/Albert Einstein College of Medicine, New York, New York.
⁵ Department of Medicine, Baylor College of Medicine, Houston, Texas.
⁶ Department of Medicine, Aga Khan University, Karachi, Pakistan.
⁷ John Ochsner Heart and Vascular Institute, Department of Cardiovascular Diseases, Ochsner Clinical School, The University of Queensland School of Medicine, New Orleans, Louisiana.

No abstract available

Plain language summary

This cross-sectional study compares the prevalence, awareness, and treatment of elevated low-density lipoprotein (LDL) cholesterol in US adults in 1999-2000 vs 2017-2020.

MeSH terms

Adult
Cholesterol, LDL
Humans
Hypercholesterolemia* / drug therapy
Hypercholesterolemia* / epidemiology
Nutrition Surveys
Prevalence

Substances

Cholesterol, LDL